

March 31, 2026

**Subject** Invitation to the 2026 Annual General Meeting of Shareholders

**To** Shareholders of Bangkok Genomics Innovation Public Company Limited

**Enclosures**

- 1.Minutes of the 2025 Annual General Meeting of Shareholders
- 2.The Company’s Articles of Association (relating to shareholders’ meetings and voting procedures)
- 3.Information of independent directors for consideration as proxy holders
- 4.Profiles of persons nominated for appointments as directors in replacement of those retiring by rotation for the year 2026
- 5.Details for consideration of the appointment of the auditor and the auditor’s profile
- 6.Procedures for registration and guidelines for attending the 2026 Annual General Meeting of Shareholders via electronic means (E-AGM)
- 7.Identification documents required for verification of the right to attend the shareholders’ meeting
- 8.Proxy Forms A, B, and C (Form B is recommended)
- 9.The 2025 Annual Report (Form 56-1 One Report) in QR Code format
- 10.Personal Data Protection Notice (Privacy Notice)

The Board of Directors’ Meeting of Bangkok Genomics Innovation Public Company Limited (the “Company”) No. 1/2026 resolved to convene the 2026 Annual General Meeting of Shareholders on 28 April 2026 at 10:30 hours. The meeting will be conducted exclusively via electronic means (E-AGM) in accordance with the rules and regulations governing electronic meetings.

The Company has also set 13 March 2026 as the Record Date for determining the list of shareholders entitled to attend the 2026 Annual General Meeting of Shareholders.

The Company hereby informs the agenda of the 2026 Annual General Meeting of Shareholders, as resolved by the Board of Directors, as follows:

**Agenda Item 1 Chairman’s Report**

Objective and Reason: This agenda item is for the Chairman to address the meeting on matters beneficial to shareholders.

The Board of Directors’ Opinion: For acknowledgment.

Required Vote: This agenda item is for acknowledgment; therefore, no voting is required.

## **Agenda Item 2 To consider and adopt the minutes of the Annual General Meeting of Shareholders 2025**

Objective and Reason: The Company held the 2025 Annual General Meeting of Shareholders on 28 April 2025. A copy of the minutes of such meeting is attached as Enclosure 1.

The Board of Directors' Opinion: The Board of Directors is of the opinion that the minutes have been accurately and completely recorded in accordance with the resolutions passed by the shareholders at such meeting. Therefore, it is deemed appropriate to propose that the shareholders' meeting consider and approve the minutes of the 2025 Annual General Meeting of Shareholders held on 28 April 2025, as a correct record of the Company.

Required Vote: This agenda item requires approval by a majority vote of the shareholders present at the meeting and casting their votes.

## **Agenda Item 3 To acknowledge the reports of board of directors and operating results for the year ended 31 December 2025**

Objective and Reason: The Company's operating results for the year 2025 are detailed in the 2025 Annual Report (Form 56-1 One Report), as shown in Enclosure 9.

The Board of Directors' Opinion: The Board of Directors deems it appropriate to propose that the Annual General Meeting of Shareholders acknowledge the Company's 2025 Annual Report.

Required Vote: This agenda item is for acknowledgment; therefore, no voting is required.

## **Agenda Item 4 To consider and approve the financial statements for the year ended 31 December 2025**

Objective and Reason: Pursuant to Section 112 of the Public Limited Companies Act B.E. 2535 (including any amendments) (the "Public Limited Companies Act") and Article 55 of the Company's Articles of Association, the Board of Directors is required to prepare the statement of financial position and the profit and loss statement as at the end of the Company's fiscal year for submission to the Annual General Meeting of Shareholders for approval. The Board must also arrange for the auditor to complete the audit prior to submission to the shareholders' meeting.

The Company has prepared the financial statements for the year 2025 ended 31 December 2025, details of which are set out in Part 3: Financial Statements of the Annual Report (Form 56-1 One Report), as shown in Enclosure 9. The key highlights are summarized as follows:

(Unit: Million Baht)

| Items                                 | Consolidated<br>Financial Statements |        | Separate Financial Statements |        |
|---------------------------------------|--------------------------------------|--------|-------------------------------|--------|
|                                       | 2025<br>(Proposed Year)              | 2025   | 2025<br>(Proposed Year)       | 2024   |
| Total Assets                          | 701.86                               | 607.59 | 691.57                        | 605.75 |
| Total Liabilities                     | 148.71                               | 68.44  | 141.80                        | 68.40  |
| Shareholders' Equity                  | 553.15                               | 539.15 | 549.77                        | 537.35 |
| Paid-up Capital                       | 300.00                               | 300.00 | 300.00                        | 300.00 |
| Total Revenue                         | 379.51                               | 337.59 | 369.96                        | 337.59 |
| Net Profit                            | 45.33                                | 50.16  | 43.74                         | 50.32  |
| Basic Earnings Per Share (Baht/Share) | 0.08                                 | 0.09   | 0.07                          | 0.09   |

The Board of Directors' Opinion: The Board of Directors deems it appropriate to propose that the Annual General Meeting of Shareholders consider and approve the Company's financial statements for the year ended 31 December 2025, which have been audited and certified by the Company's auditor, Virach & Associates Office Co., Ltd. The financial statements have also been reviewed by the Audit Committee and approved by the Board of Directors' Meeting on 25 February 2026.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

#### **Agenda Item 5 To consider and approve the allocation of the net profit as a legal reserve and dividend payment**

Objective and Reason:

1. In accordance with Section 116 of the Public Limited Companies Act and Article 50 of the Company's Articles of Association, the Company is required to allocate a portion of its annual net profit as a legal reserve, at a rate of no less than 5% of the annual net profit, after deducting any accumulated losses carried forward (if any), until the reserve reaches at least 10% of the registered capital.

2. The Company has a dividend policy to distribute dividends to shareholders at a rate of no less than 40% of the net profit from the Company's separate financial statements, after deducting corporate income tax and allocating the required legal reserve. However, the Company may consider paying dividends at a different rate from the stated policy, depending on its operating performance, financial position, liquidity, working capital requirements, business expansion plans, and overall economic conditions.

3. The dividend payment information based on the operating results for the year 2025 is as follows:

| Details of Dividend Payment                          | 2025 (Proposed Year) | 2024        |
|--|----------------------|-------------|
| Net profit from separate financial statements (Baht) | 43,741,279           | 50,318,711  |
| Number of shared (shares)                            | 600,000,000          | 600,000,000 |
| Legal Reserve as of December 31 (Baht)               | 13,200,000           | 11,000,000  |
| Dividend Payment Rate (Baht/Share)                   | 0.05                 | 0.05        |
| Total Dividend Payment (Baht)                        | 30,000,000           | 30,000,000  |
| Dividend Payout Ratio to Net Profit (%)              | 68.59                | 59.62       |

The Board of Directors' Opinion: The Board of Directors has considered various factors, including the Company's operating results and dividend payment policy, and deems it appropriate to propose that the Annual General Meeting of Shareholders consider and approve the following:

- 1) Approval of the allocation of net profit for the year 2025 as a legal reserve in the amount of Baht 2,200,000, representing not less than 5% of the Company's net profit.
- 2) Approval of the dividend payment for the operating results of the year 2025 at the rate of Baht 0.05 per share, totaling Baht 30,000,000.

In this regard, the Company has set the Record Date for determining the shareholders entitled to receive dividends on 7 May 2026, and the dividend payment date is scheduled for 28 May 2026. However, the entitlement to receive such dividends remains subject to approval by the 2026 Annual General Meeting of Shareholders.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes

#### **Agenda Item 6 To consider and approve the directors' remuneration for the year 2026**

Objective and Reason: Pursuant to Section 90 of the Public Limited Companies Act, the payment of directors' remuneration must be in accordance with the company's Articles of Association and approved by a resolution of the shareholders' meeting with a vote of not less than two-thirds (2/3) of the total number of votes of shareholders present at the meeting.

In addition, Article 33 of the Company's Articles of Association stipulates that directors are entitled to receive remuneration from the Company in the form of rewards, meeting allowances, gratuities, bonuses, or other benefits as specified in the Articles of Association or as approved by the shareholders' meeting. Such remuneration may be fixed as a definite amount or determined based on criteria and may be set from time to time or remain effective until amended. Directors are also entitled to per diem allowances and other welfare benefits in accordance with the Company's regulations.

The Board of Directors, having been appropriately reviewed by the Executive Committee, has considered the principles for determining directors' remuneration by considering its appropriateness in line with companies listed in the same industry, as well as the Company's operating results, business size, responsibilities of the Board,

and net profit. The Board therefore deems it appropriate to propose maintaining all components of directors' remuneration at the same rates as in 2025, with details as follows:

Monthly Remuneration of the Board of Directors (Baht/person)

| Position              | 2026 (Proposed Year) | 2025   |
|-----------------------|----------------------|--------|
| Chairman of the Board | 50,000               | 50,000 |
| กรรมการ               | 40,000               | 40,000 |

Meeting Allowance for Sub-committees. (Audit Committee and Executive Committee) (Baht/person/time)

| Position              | 2026 (Proposed Year) | 2025   |
|-----------------------|----------------------|--------|
| Chairman of the Board | 20,000               | 20,000 |
| Directors             | 15,000               | 15,000 |

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors.

(Chief Executive Officer and Deputy Chief Executive Officer)

The Board of Directors' Opinion: It is deemed appropriate to propose that the Annual General Meeting of Shareholders consider and approve the determination of remuneration for the Board of Directors and sub-committees for the year 2026, including monthly remuneration and meeting allowances, at the same rates as in 2025.

In this regard, it is also deemed appropriate to propose that the shareholders' meeting consider and approve the payment of a bonus to the Board of Directors at a rate of 5% of the Company's net profit for the year 2026.

Required Vote: This agenda item must be approved by a vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting.

**Agenda Item 7 To consider and approve the appointment of directors in replacement of those who must retire by rotation**

Objective and Reason: In accordance with Section 71 of the Public Limited Companies Act and Article 18 of the Company's Articles of Association, at every Annual General Meeting of Shareholders, one-third (1/3) of the directors, or if it is not a multiple of three, then the number nearest to one-third (1/3) must retire from office. There must be a drawing by lots to determine the directors' retirement in the first and second years following the registration of the Company. In each subsequent year, the directors who occupy the position for the longest period must retire. A retiring director is eligible for re-election. Currently, the Company has a total of 11 directors. At the Annual General Meeting of Shareholders for the year 2026, four (4) directors are required to retire by rotation, as follows:

|                 |                |   |
|-----------------|----------------|---|
| 1. Mr. Goanpot  | Asvinvichit    | Chairman of the Executive Committee       |
| 2. Mr. Preecha  | Laohapongchana | Executive Director                        |
| 3. Dr. Saowalak | Dansakul       | Director / Chief Executive Officer        |
| 4. Mr. Xiaohan  | Wang           | Director / Deputy Chief Executive Officer |

The Board of Directors' Opinion: The Board of Directors, excluding the interested directors, has considered it appropriate to propose to the Annual General Meeting of Shareholders for the year 2026 to re-elect the four (4) directors who are due to retire by rotation, namely Mr. Goanpot Asvinvichit, Mr. Preecha Laohapongchana, Dr. Saowalak Dansakul, and Mr. Xiaohan Wang, to continue serving as directors for another term.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

#### **Agenda Item 8 To consider and approve the appointment of auditor and fix his/her remuneration for the year 2026**

Objective and Reason: In accordance with Section 120 of the Public Limited Companies Act and Articles 58 and 59 of the Company's Articles of Association, the Annual General Meeting of Shareholders is required to appoint the Company's auditor and determine the audit fee annually.

The Audit Committee has considered and selected Dr. Virach & Associates Office Co., Ltd. as the Company's audit firm for the year 2025. This selection is based on the firm's approval by the Securities and Exchange Commission (SEC), maintains internationally recognized auditing standards, and has demonstrated expertise in auditing with consistent efficiency, quality, and reliability. The firm has performed well in past audits, ensuring timely and credible financial reviews. Additionally, a comparison of work volume and audit fees with similar firms confirms that Dr. Virach & Associates Office Co., Ltd. offers reasonable audit fees.

The names of the auditors who will express an opinion on the Company's financial statements and sign the financial reports, along with other relevant details, are provided in Enclosure 5.

The Board of Directors' Opinion: The Board of Directors concurs with the Audit Committee's recommendation and proposes to the Annual General Meeting of Shareholders 2025 to appoint

1. Dr. Virach Aphimeteetamrong (Certified Public Accountant No. 1378)
2. Mr. Chaikorn Aunpitipongsa (Certified Public Accountant No. 3196) or
3. Mr. Apiruk Ati-anuwat (Certified Public Accountant No. 5202)

of Dr. Virach & Associates Office Co., Ltd. as the Company's auditors for 2025.

The audit firm and the nominated auditors have no relationships or conflicts of interest with the Company, its executives, major shareholders, or related persons.

Additionally, the Board deems it appropriate to propose that the Annual General Meeting of Shareholders approve the audit fee for 2025 in the amount of 1,830,000 Baht, covering the annual financial statement audit, quarterly financial statement audits, investment promotion certificate audit, consolidated annual financial statement audit, and consolidated quarterly financial statement audits.

However, this audit fee does not include non-audit service fees.

Required Vote: This agenda item must be approved by a majority vote of the shareholders present at the Meeting and casting their votes.

#### **Agenda Item 9 Other matters (If any)**

The Company provides shareholders with the opportunity to submit questions related to the agenda of the Annual General Meeting of Shareholders for the year 2026 or other important matters of the Company in advance of the meeting date via email at [BKGL\\_IR@bangkokgenomics.com](mailto:BKGL_IR@bangkokgenomics.com) so that the Board of Directors or management can prepare information for clarification accordingly.

The Company hereby invites shareholders to attend the Annual General Meeting of Shareholders for the year 2026 on April 28, 2026, at 10:30 hours. The meeting will be conducted solely via electronic means in accordance with the rules and regulations governing electronic meetings

Shareholders may study the procedures and methods for registration to attend the 2026 Annual General Meeting via electronic means, as well as proxy appointment procedures, as detailed in Enclosure 6.

For shareholders who wish to attend the meeting in person via electronic means or to appoint a proxy (other than an independent director of the Company) to attend the meeting via electronic means, registration or proxy appointment can be completed through the AFF E-Meeting system in accordance with the procedures specified in Enclosure 6, from April 10, 2026, until the completion of the meeting on April 28, 2026.

For shareholders who wish to appoint an independent director of the Company as proxy, as listed and detailed in Enclosure 3, such shareholders may appoint a proxy through the AFF E-Meeting system in accordance with the procedures in Enclosure 6, or may submit the proxy form by registered mail to the Investor Relations Department, Bangkok Genomics Innovation Public Company Limited, No. 3689 Rama IV Road, Phra Khanong Subdistrict, Khlong Toei District, Bangkok 10110, from April 10, 2026 until April 24, 2026. In this regard, the proxy documents sent by registered mail must be received by the Company no later than April 24, 2026.

Details of the documents and evidence required for registration via the AFF E-Meeting system, supporting documents for proxy appointment, and voting procedures at the shareholders' meeting are provided in Enclosure 7.

Upon verification of the registration and documents submitted by shareholders, and after confirming the list of shareholders entitled to attend the Annual General Meeting of Shareholders for the year 2026 as of the Record Date on March 13, 2026, Affinity Relation Co., Ltd., the certified electronic meeting control system provider approved by the Electronic Transactions Development Agency (ETDA), will send a link to access the electronic meeting system to shareholders via the email address provided to the Company.

The Company recommends the use of Proxy Form B (as per Enclosure 8), which allows shareholders to clearly specify their voting instructions. The meeting will be conducted in accordance with the Company's Articles of Association as detailed in Enclosure 2.

On the date of the Annual General Meeting of Shareholders for the year 2026, shareholders or their proxies (if applicable) are requested to join the meeting via the link sent to the registered email address. The system will be open for registration from 08:30 hours on April 28, 2026, and the meeting will commence at 10:30 hours.

To support environmental sustainability, the Company has provided the 2025 Annual Report (Form 56-1 One Report) in QR Code format, as detailed in Enclosure 9.

Yours faithfully,

- Saowalak Dansakul -  
(Ms.Saowalak Dansakul)  
Chief Executive Officer